News
Sagimet Announces Oral Presentation Of Data From The Phase 2b FASCINATE-2 Study Of Denifanstat In MASH At EASL International Liver Congress 2024
7 May 24
Biotech, News, General
Sagimet Biosciences Announces Appointment Of Thierry Chauche As Chief Financial Officer, Effective May 6, 2024
6 May 24
News, Management
HC Wainwright & Co. Initiates Coverage On Sagimet Biosciences with Buy Rating, Announces Price Target of $32
2 May 24
News, Price Target, Initiation, Analyst Ratings
Sagimet Biosciences Announces Completion Of Phase 1 Hepatic Impairment Study With FASN Inhibitor Denifanstat
27 Mar 24
Biotech, News, General
Goldman Sachs Maintains Buy on Sagimet Biosciences, Lowers Price Target to $27
26 Mar 24
News, Price Target, Analyst Ratings
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
25 Mar 24
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
12 Health Care Stocks Moving In Monday's Intraday Session
25 Mar 24
Movers
Leerink Partners Initiates Coverage On Sagimet Biosciences with Outperform Rating, Announces Price Target of $26
25 Mar 24
News, Price Target, Initiation, Analyst Ratings
12 Health Care Stocks Moving In Friday's After-Market Session
16 Feb 24
Movers
Press releases
Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024
7 May 24
News, Press Releases
Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat
27 Mar 24
Health Care, Press Releases
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors
25 Mar 24
News, Management, Press Releases
Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates
25 Mar 24
Earnings, Press Releases